NCT04958031: A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy |
|
|
| Active, not recruiting | 2 | 75 | Canada, US | CVL-871 1.0 mg, CVL-871 3.0 mg, Placebo | Cerevel Therapeutics, LLC | Apathy in Dementia | 01/25 | 02/25 | | |